拓邦股份(002139.SZ):中標中移動約1.75億元通信用磷酸鐵鋰電池產品集中採購項目
格隆匯7月28日丨拓邦股份(002139.SZ)公佈,公司於2021年7月28日收到中國移動通信有限公司(“中國移動”)招標代理機構簽發的《中標通知書》,確定公司為“中國移動2021年至2022年通信用磷酸鐵鋰電池產品集中採購項目”的中標單位,中標金額約17534.12萬元人民幣(不含税)。
公司在鋰電應用領域深耕多年,具備多類型電芯、PACK 研發製造能力,為客户提供各類鋰電池儲能產品和系統解決方案。隨着5G 基礎設施建設,通信用鋰電池需求仍將持續,公司將繼續開拓國內外通信鋰電池業務,擴大通信後備電源產品銷售規模。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.